Aspira Women's Health

Aspira Women’s Health is a women’s health company focused on improving gynecologic care through data-driven diagnostics, clinical research, and technology. Its testing solutions help healthcare providers assess the risk of malignancy in patients with adnexal masses and support informed decisions about monitoring or surgery. Aspira’s OvaSuite portfolio includes OvaWatch, designed for masses initially assessed as indeterminate or likely benign, with longitudinal monitoring to help providers track risk over time.

For masses planned for surgery, Ova1 and Ova1Plus provide personalized risk assessment using biomarkers, including CA-125, menopausal status, and ultrasound findings. Ova1Plus follows a reflex process in which Overa is performed when Ova1 indicates intermediate risk. The company also offers test kits and resources for patients and providers, including ordering information, specimen collection guidance, educational materials, and insurance and billing support.

Aspira’s research and development work draws on clinical expertise and peer-reviewed evidence to pursue earlier risk assessment, more accurate diagnoses, and personalized care strategies